Bevirimat

Bevirimat

SCHEMBL12465626

C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CCC(OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 1.00
PRKCD Q05655 1/20 0.78
CETP P11597 1/20 0.76
NT5E P21589 9/20 0.73
PRKCG P05129 2/20 0.69
GPBAR1 Q8TDU6 2/20 0.66
USP2 O75604 1/20 0.66
LMNA P02545 1/20 0.66
HIF1A Q16665 1/20 0.66
AKR1B10 O60218 1/20 0.66
ALB P02768 1/20 0.66
POLB P06746 1/20 0.66
GLI1 P08151 1/20 0.66
AKR1B1 P15121 1/20 0.66
DPP4 P27487 1/20 0.66
RORC P51449 1/20 0.66
SAE1 Q9UBE0 1/20 0.66
UBA2 Q9UBT2 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bevirimat SCHEMBL12565073 1.00 PTPN1 (1.00) PTPN1PRKCDCETPNT5EPRKCG
Bevirimat SCHEMBL19480543 1.00 PTPN1 (1.00) PTPN1PRKCDCETPNT5EPRKCG
Bevirimat SCHEMBL2612026 1.00 PTPN1 (1.00) PTPN1PRKCDCETPNT5EPRKCG
Bevirimat SCHEMBL16272373 1.00 PTPN1 (1.00) PTPN1PRKCDCETPNT5EPRKCG
Bevirimat SCHEMBL10061308 1.00 PTPN1 (1.00) PTPN1PRKCDCETPNT5EPRKCG
SCHEMBL13222940 0.95 PTPN1 (0.91) PTPN1PRKCDCETPNT5EPRKCG
SCHEMBL2620136 0.94 PTPN1 (0.88) PTPN1PRKCDCETPNT5EPRKCG
SCHEMBL16330184 0.94 PTPN1 (0.88) PTPN1PRKCDCETPNT5EPRKCG
SCHEMBL12915116 0.94 PTPN1 (0.88) PTPN1PRKCDCETPNT5EPRKCG
SCHEMBL13075129 0.94 PTPN1 (0.88) PTPN1PRKCDCETPNT5EPRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3411381-A1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV Healthcare UK (No.5) Limited (GB) 2018-12-12 EP disclosed
EP-3218388-A1 C17-ARYL SUBSTITUTED BETULINIC ACID ANALOGS VIIV Healthcare UK (No.5) Limited (GB) 2017-09-20 EP disclosed
EP-3218389-A1 EXTENDED BETULINIC ACID ANALOGS VIIV Healthcare UK (No.5) Limited (GB) 2017-09-20 EP disclosed
EP-3218387-A1 OXOLUPENE DERIVATIVES VIIV Healthcare UK (No.5) Limited (GB) 2017-09-20 EP disclosed
WO-2017134596-A1 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS VIIV Healthcare UK (No.5) Limited (GB) 2017-08-10 WO disclosed
EP-3129392-A1 TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT VIIV Healthcare UK(No.4) Limited (GB) 2017-02-15 EP disclosed
WO-2016077561-A1 OXOLUPENE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-19 WO disclosed
WO-2016077569-A1 C17-ARYL SUBSTITUTED BETULINIC ACID ANALOGS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-19 WO disclosed
WO-2016077572-A1 EXTENDED BETULINIC ACID ANALOGS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-19 WO disclosed
WO-2015195776-A1 BETULINIC ACID DERIVATIVES WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-23 WO disclosed
WO-2015157483-A1 TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-15 WO disclosed
EP-2847208-A1 C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY Bristol-Myers Squibb Company (US) 2015-03-18 EP disclosed
EP-2814834-A1 C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY Bristol-Myers Squibb Company (US) 2014-12-24 EP disclosed
WO-2014123889-A1 C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-14 WO disclosed
EP-2758419-A1 NOVEL BETULINIC ACID DERIVATIVES WITH ANTIVIRAL ACTIVITY Bristol-Myers Squibb Company (US) 2014-07-30 EP disclosed
EP-2670765-A1 C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY Bristol-Myers Squibb Company (US) 2013-12-11 EP disclosed
WO-2013169578-A1 C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-14 WO disclosed
WO-2013123019-A1 C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-22 WO disclosed
WO-2013043778-A1 NOVEL BETULINIC ACID DERIVATIVES WITH ANTIVIRAL ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-28 WO disclosed
WO-2012106190-A1 C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-09 WO disclosed